



GLOBAL JOURNAL OF MEDICAL RESEARCH

Volume 12 Issue 4 Version 1.0 April 2012

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN : 0975-5888

Respiratory Syncytial Virus Infection: IgA & LT-E4 Responses and Effects of Host Factors for Infants with Acute Bronchiolitis in Two Iraqi Pediatric Hospitals

By Afrah,G.Salih , Kassim,J.Al-Shamma , Mahir,M.Hassan , Raed ,Y.Salman
& Israa ,M.Salih

University of Baghdad

Abstract - Background : Respiratory syncytial virus (**RSV**) is a leading cause of lower respiratory tract disease in infants and young children. Both the magnitude , intensity of infection and the host response to **RSV** infection determine the severity and intensity of disease.

Objective : Our goal was to evaluate the effect of immune response (**RSV** IgA) and inflammatory mediators (LT-E4), in addition to the influence of host factors on the severity of the disease.

Keywords : *Pediatric; RSV, Respiratory Syncytial Virus IgA (RSV-IgA); Leukotriene E-4(LT-E4), Bronchiolitis.; Cysteinyl Leukotrienes; Secondhand Cigarette Smoke; Infants; Parental Asthma.*

GJMR-B Classification : *FOR Code: WF 140, WC 515, WC 505*



Strictly as per the compliance and regulations of:



Respiratory Syncytial Virus Infection: IgA & LT-E4 Responses and Effects of Host Factors for Infants with Acute Bronchiolitis in Two Iraqi Pediatric Hospitals

Afrah, G. Salih ^α, Kassim, J. Al-Shamma ^σ, Mahir, M. Hassan ^ρ, Raed, Y. Salman ^ω,
& Israa, M. Salih [¥]

Abstract - Background : Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants and young children. Both the magnitude, intensity of infection and the host response to RSV infection determine the severity and intensity of disease.

Objective : Our goal was to evaluate the effect of immune response (RSV IgA) and inflammatory mediators (LT-E4), in addition to the influence of host factors on the severity of the disease.

Methods : This was a randomized, prospective study in two Iraqi pediatric hospitals. One hundred and twenty-three infants (mean age: 6.99 ± 0.62 , 71 boys & 52 girls), with a first episode of acute bronchiolitis were randomly divided into eight treatment groups: oxygen plus intravenous fluid, montelukast pediatric chewable tablet, salbutamol syrup, salbutamol nebulizer, combination of both oral plus nebulized salbutamol, dexamethasone IV injection, hydrocortisone IV injection, and azithromycin suspension. Control infants with non respiratory diseases were also studied for comparisons. The measured parameters were RSV IgA titer, LT-E4 titer, and a variety of environmental and host factors that may contribute to the severity of RSV bronchiolitis. Severity of bronchiolitis was based on the quantization of lowest O₂ saturation and the length of hospital stay.

Results : There was a significant increase in RSV IgA values in patients (1.58 ± 0.24 U/mL) compared to the control (0.36 ± 0.03 U/mL); also there was a significant increase in the leukotriene E₄ values in patients (2.66 ± 0.52 ng/ml) compared to the control infants (0.15 ± 0.007 ng/ml). Age was found to be a significant factor in the severity of infection. The younger an infant was, the more severe the infection tended to be as measured by the lowest oxygen (O₂) saturation. We also found that infants exposed to postnatal cigarette smoke from the mother had a lower O₂ saturation than those not exposed. Although a history of maternal atopy seemed to be protective.

Conclusion : Secretory IgA antibodies level was found to be a good indicator to respiratory syncytial virus infection as seen by significantly higher levels in patients compared to the

control infants. The severity of RSV bronchiolitis early in life seems modified by postnatal maternal cigarette smoke exposure, atopy and age of the infants.

Keywords : Pediatric; RSV; Respiratory Syncytial Virus IgA (RSV-IgA); Leukotriene E-4 (LT-E4), Bronchiolitis; Cysteinyl Leukotrienes; Secondhand Cigarette Smoke; Infants; Parental Asthma.

I. INTRODUCTION

Respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract infections in infants and young children throughout the world (1). RSV replicates for 1–3 days before producing lower respiratory tract symptoms affecting almost 60% of infants and up to 25% of toddlers and preschoolers. Current treatment approaches for severe RSV induced disease are ineffective. Therefore, prevention of disease is a high priority. Immunoglobulin A (IgA) is the most abundant immunoglobulin in mammals. Unlike other antibody isotypes, IgA is targeted to mucosal tissues, and virus-specific IgA in mucosal secretions has been shown to protect from reinfection. IgA, unlike IgG, is able to bind and neutralize viral proteins intracellularly at the site of initial replication in epithelial cells. Therefore; mucosal IgA may be of particular importance in immunity against RSV, which is a mucosally restricted pathogen (2,3). Inflammatory mechanisms in bronchiolitis have been documented recently, including increased airway secretion, mucosal edema, and infiltration of inflammatory cells. Cysteinyl leukotrienes (CysLTs) are released during respiratory syncytial virus (RSV) airway infection in infants, and their levels are significantly elevated. CysLTs are known to cause bronchial obstruction, mucosal edema, and infiltration of eosinophilic granulocytes and to increase bronchial responsiveness (4). CysLTE₄ (LTE₄), one of the terminal cysLT metabolites, is significantly increased in the infants hospitalized with RSV bronchiolitis (5). The risk of severe RSV disease is increased by factors that compromise the ability to control and withstand a respiratory tract infection. Therefore; environmental factors also play a role, including ones that affect lung

Author α : Department of clinical pharmacy, college of pharmacy, university of Baghdad. E-mail : frah72@yahoo.com

Author ρ : Manager of Child's Central Teaching Hospital.

Author ω : Senior specialist in internal pediatric disease in Child's Central Teaching Hospital.

Author ¥ : Senior specialist in internal pediatric disease in Karbala Pediatric Teaching Hospital.

function (e.g., household tobacco use) or that increase exposure to infection (e.g., day care, hospitalization, multiple siblings, crowding) (6,7). The objective of the present randomized, prospective study was to evaluate the effects of immune response, inflammatory mediators, host and environmental factors on the severity of the acute viral bronchiolitis.

II. MATERIALS & METHODS

This prospective study was conducted in two Iraqi pediatric hospitals. Baghdad Health Office/Karkh, Child's Central Teaching Hospital & Karbala Health Office, Karbala Pediatric Teaching Hospital. Inclusion criteria were infants' patients aged >8 weeks and <2 years with a respiratory symptom duration of <4 days. Additional inclusion criteria included first episode of wheezing or shortness of breath, randomization within 12 hours of admission and informed consent. Exclusion criteria were any previous hospital admissions with respiratory illnesses, had ever been treated with anti-asthma medications before the current illness, corticosteroids treatment in any form during current illness, and underlying cardiopulmonary disease. Gender, age, weight, height, body temperature, family history in (first-degree relatives), of asthma, atopy, tobacco smoking, usage of kerosene heater, type of feeding, duration of exclusive breast feeding, concurrent diseases, and concomitant medications, were recorded for each infants. A total number of 123 patients mean age: 6.99 ± 0.62 with mild to moderate bronchiolitis were divided randomly into eight treatment groups:

Group A: Ten infants' patients had received oxygen + intravenous fluid. Group B: Fourteen infants' patients had received study treatment, montelukast pediatric chewable tablet 4mg once daily, if vomiting occurred one additional dose was given (4). Group C: Ten infants patient had received azithromycin suspension (200mg/5ml), with a dose of 10 mg /kg once daily. Group D: Ten infants' patients had received hydrocortisone vial (100 mg/2ml), with a dose of, 5-10 mg/kg/dose q 6hour IV. Group E: Twenty infants' patients had received salbutamol syrup (2mg/5ml), with a dose of, 0.1-0.3 mg/kg/dose q 8 hour; the method of syrup administration was taught to the caregiver. Any patient who vomited the drug within 15 minutes of ingestion was advised to have a repeat dose (8). Group F: Twenty infants' patients had received salbutamol given in combination as syrup & by nebulization, (oral salbutamol 0.1-0.3mg/kg/dose q8 hour+salbutamol nebulizer 0.01-0.02 mg/kg /dose q6hour). Group G: Twenty infants' patients had received dexamethasone ampule (4mg/1ml), with a dose of, 0.25 -0.5 mg/kg/dose q 12 hours intravenously. Group H: Nineteen infants' patients had received salubutamol solution for nebulizer (5mg/ml), with a dose of, 0.01-0.02 mg/kg /dose q 6 hour.

From all enrolled infants, blood samples were taken and try to measure both (RSV IgA) & LT-E4, antibody to RSV & inflammatory mediators that release during RSV acute bronchiolitis, respectively. These parameters were measured by the enzyme linked immunoassays (ELISA), to investigate the etiology of acute respiratory infections in hospitalized infants. The test was explained to the parents and they signed the informed consent form. The obtained optical density (OD) of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method (9,10).

Other type of samples that taken from the patients that put on the study treatment, montelukast pediatric chewable 4mg tablets, was the nasal swab. In the present study, we prospectively tried to examine the association between the presence of nasal eosinophils and severity of acute bronchiolitis and the effect of montelukast on nasal eosinophil. In this study we tried to quantify the number of neutrophils and eosinophils in nasal secretions by utilizing the semiquantitative nasal cytology grading score by Meltzer^(11,12).

III. RESULTS

Table 1 : Demographic data and baseline characters of patients and control infants. The data were expressed as number (n), and percentage (%).

	Patients (n _{total} =123)	Control Infants (n _{total} =10)
Characteristics	(n,%)	(n,%)
Age <6months.	73 (59)	4(40)
Age >6months.	50 (41)	6 (60)
Male.	71 (58)	7 (70)
Female.	52 (42)	3 (30)
Family history of Asthma.	64 (52)	4 (40)
Family history of Atopy.	78 (63)	6 (60)
History Of Passive Tobacco Smoking.	91(74)	8 (80)
Family history of Kerosene Heating.	95 (77)	7 (70)
Presence of pets at house.	55 (45)	5 (50)
Breast Feeding.	67 (54)	1 (10)
Bottle feeding.	37 (30)	7 (70)
Mixed Feeding.	16 (13)	2 (20)
< 5 Member.	16(13)	2(20)
>5 Member.	107(87)	8(80)
Mean Weight, kg.	7.2 ± 0.79	9.3 ± 1.14
Duration Of Exclusive Breast Feeding, months.	4.53± 0.303	8 ± 2.68
The values of weight,& duration of exclusive were expressed as mean ± standard error of mean (SEM).		

Table (1), demonstrated that, there were no significant differences between the groups in terms of demographic variables.

Table 2 : Relationships between host factors and RSV IgA titer for infants' patients with acute viral bronchiolitis and for the control infants. Data were expressed as mean \pm standard error of mean (SEM), number (n) and percent (%).

		RSV IgA		RSV IgA
	Patients	U/ml	Control	U/ml
	n , (%)	Patient	n , (%)	Control
	total = 45		total = 10	
RSV IgA High Titer (mean \pm SEM)		1.58* \pm 0.24		0.36 \pm 0.03
RSV IgA Low Titer (mean \pm SEM)		0.39 \pm 0.02		
Age <1year.	34 (75.6)	1.24* \pm 0.28	7,(70)	0.31 \pm 0.03
Age >1 year.	11 (24.4)	2.63 * \pm 0.39 †	3,(30)	0.36 \pm 0.06
Male.	34 (75.6)	1.37 * \pm 0.19	7,(70)	0.35 \pm 0.03
Female.	11 (24.4)	2.23* \pm 0.78	3,(30)	0.29 \pm 0.03
Positive Family history of Asthma.	21,(46.6)	1.21* \pm 0.21	3,(30)	0.36 \pm 0.06
Negative Family history of Asthma.	24(53.3)	1.91 * \pm 0.41	7,(70)	0.32 \pm 0.03
Positive Family history of Atopy.	33 (73.3)	1.18* \pm 0.15	6,(60)	0.33 \pm 0.03
Negative Family history of Atopy.	12 (26.6)	2.69 * \pm 0.74 †	4,(40)	0.33 \pm 0.05
Positive History Of Passive Tobacco Smoking.	35 (77.7)	1.79* \pm 0.30	8,(80)	0.32 \pm 0.03
Negative History Of Passive Tobacco Smoking.	10(22.2)	0.86* \pm 0.13 †	2,(20)	0.36 \pm 0.09
Positive Family history of Kerosene Heating.	38 (84.4)	1.49 * \pm 0.19	7(70)	0.32 \pm 0.03
Negative Family history of Kerosene Heating.	7 (15.6)	2.21* \pm 1.19	3 (30)	0.36 \pm 0.001
Positive Presence of Animal in the house.	20(44.4)	1.26* \pm 0.22	3 (30)	0.30 \pm 0.029
Negative Presence of Animal in the house.	25 (55.5)	1.84* \pm 0.39	7(70)	0.35 \pm 0.04
Positive Breast Feeding.	22(48.8)	1.73* \pm 0.43	3,(30)	0.26 \pm 0.006
Negative Breast Feeding.	23 (51.1)	1.44 * \pm 0.25	7,(70)	0.36 \pm 0.03 †
Positive Bottle feeding.	21,(46.6)	1.41* \pm 0.25	7,(70)	0.35 \pm 0.03
Negative Bottle feeding.	24,(53.3)	1.73* \pm 0.4	3,(30)	0.26 \pm 0.006
Number Of Family Member > 5.	36 ,(80)	1.5 * \pm 0.28	8 ,(80)	0.35 \pm 0.03
Number Of Family Member < 5.	9 ,(20)	1.91* \pm 0.53	2 ,(20)	0.26 \pm 0.009 †
*P<0.05: Significant difference between patients and control group. †P<0.05: significant difference from preceding value. RSV IgA = Respiratory Syncytial Virus Immunoglobuline A. Control :infants with non respiratory illness				

The table (2) showed the RSV IgA values for infants' patients with acute viral bronchiolitis, together with RSV IgA values for the control infants. There was a significant increase in RSV IgA values in patients compared to the control infants.

There was a significant relationships between titer of the antibody against RSV(RSV IgA) and family history of atopy,tobacco smoking ,and the ages of infants patients.

Table 3 : Relationships between host factors and leukotriene -E4 for infants' patients with acute viral bronchiolitis and for the control infants. Data were expressed as mean \pm standard error of mean (SEM), number (n) and percent (%).

	Patients	Patients	Control	Control
	n , (%)	LTE4	n , (%)	LTE4
	total = 48	ng / ml	total = 10	ng / ml
LT-E4 High Titer.		2.66 * \pm 0.52		0.15 \pm 0.007
LT-E4 Low Titer.		0.142 \pm 0.004		
Age <1year.	36 (75)	2.46* \pm 0.6	7,(70)	0.14 \pm 0.006
Age >1 year.	12 (25)	3.28 * \pm 1.1	3,(30)	0.15 \pm 0.02
Male.	34,(70.8)	2.10* \pm 0.56	7,(70)	0.14 \pm 0.01
Female.	14,(29.1)	4.25 * \pm 1.07 †	3,(30)	0.15 \pm 0.01
Positive Family history of Asthma.	23,(47.9)	1.93* \pm 0.60	3,(30)	0.15 \pm 0.02
Negative Family history of Asthma.	25 (52.1)	3.31 * \pm 0.84	7,(70)	0.14 \pm 0.006
Positive Family history of Atopy.	34 (70.8)	2.47 * \pm 0.65	6,(60)	0.15 \pm 0.01
Negative Family history of Atopy.	14 (29.1)	3.11* \pm 0.91	4,(40)	0.14 \pm 0.008
Positive History Of Passive Tobacco Smoking.	38 (79.2)	2.87 * \pm 0.63	8,(80)	0.15 \pm 0.008
Negative History Of Passive Tobacco Smoking.	10(20.8)	1.84* \pm 0.77 †	2,(20)	0.15 \pm 0.02
Positive Family history of Kerosene Heating.	40 (83.3)	2.68 * \pm 0.60	7(70)	0.15 \pm 0.01
Negative Family history of Kerosene Heating.	8 (16.6)	2.64* \pm 1.04	3 (30)	0.13 \pm 0.005
Positive Presence of Animal in the house.	20(41.6)	2.33 * \pm 0.63	5 (50)	0.15 \pm 0.01
Negative Presence of Animal in the house.	28 (58.3)	2.89 * \pm 0.78	5 (50)	0.14 \pm 0.006
Positive Breast Feeding.	29 (60.4)	3.26* \pm 0.74	3 (30)	0.15 \pm 0.01
Negative Breast Feeding.	19 (39.6)	1.74* \pm 0.66	7(70)	0.15 \pm 0.01
Positive Bottle feeding.	20 (41.6)	2.09 * \pm 0.71	7,(70)	0.15 \pm 0.01
Negative Bottle feeding.	28 (58.3)	3.06* \pm 0.74	3,(30)	0.15 \pm 0.01
Number Of Family Member > 5.	36 ,(75)	2.45* \pm 0.59	8 ,(80)	0.15 \pm 0.009
Number Of Family Member < 5.	12 ,(25)	3.43* \pm 1.31	2 ,(20)	0.14 \pm 0.002
*P<0.05: Significant difference between patients and control group.				
†P<0.05 : significant difference from the preceding value				
LT-E4= Leukotriene E 4				
Control :infants with non respiratory illness				

Table (3) showed the leukotriene E4 values in infants patients with acute bronchilitis, together with leukotriene values of the control infants. There was a significant increase in the leukotriene E4 values in patients compared to the control infants. As the table shown, only the gender and family history of tobacco smoke showed significant differences.

Table 4 : Effects of host factors on length of stay (LOS) and oxygen saturation (S_pO₂) for the infants patients with acute viral bronchiolitis .Data were expressed as mean ± standard error of mean (SEM) ,number (n) and percent (%).

	Patients	Patients	Patient
	n , (%)	LOS (day)	S _p O ₂
	total = 60		
Male.	41 (68.3)	2.9 ± 0.18	94.14 * ± 0.34
Female.	19 (31.7)	3.3 ± 0.32	93.84 * ± 0.39
Age > 1 year.	14 (23.3)	2.86 ± 0.38	94.8 * ± 0.64
Age < 1 year.	46 (76.7)	3.11 ± 0.17	93.7 * ± 0.28
Positive Family history of Asthma.	27 (45)	3.18 ± 0.24	94.41 * ± 0.35
Negative Family history of Asthma.	33 (55)	3.2 ± 0.20	93.75 * ± 0.38
Positive Family history of Atopy.	42 (70)	2.5 ± 0.23	94.16 * ± 0.31
Negative Family history of Atopy.	18 (30)	3.16 ± 0.21 †	93.77 * ± 0.51
Positive History Of Passive Tobacco Smoking.	46 (76.7)	3.26 ± 0.19	94.04 * ± 0.29
Negative History Of Passive Tobacco Smoking.	14 (23.3)	3.25 ± 0.29	94.07 * ± 0.61
Positive Family history of Kerosene Heating.	51 (85)	3.22 ± 0.19	93.90 * ± 0.28
Negative Family history of Kerosene Heating.	9 (15)	2.83 ± 0.18	94.88 * ± 0.69
Positive Presence of Animal in the house.	27 (45)	3.22 ± 0.26	94.29 * ± 0.34
Negative Presence of Animal in the house.	33 (55)	3.19 ± 0.21	94.36 * ± 0.32
Positive Breast Feeding.	31 (51.6)	2.86 ± 0.23	94.58 * ± 0.38
Negative Breast Feeding.	29 (48.3)	3.09 ± 0.23 †	93.54 * ± 0.34 †
Positive Bottle feeding.	30 (50)	3.17 ± 0.28	93.83 * ± 0.35
Negative Bottle feeding.	30 (50)	2.8 ± 0.18	94.26 * ± 0.39
Number Of Family Member > 5.	48 (80)	3.18 ± 0.19	94.12 * ± 0.28
Number Of Family Member < 5.	12 (20)	3.13 ± 0.27	93.7 * ± 0.7
RSV IgA high titer (mean ± SEM).	1.58 * ± 0.24	2.9 ± 0.14	94.2 ± 0.29
RSV IgA low (mean ± SEM).	0.39 ± 0.02	3.9 ± 0.47 †	93.06 * ± 0.58 †
LTE4 high titer (mean ± SEM).	2.66* ± 0.52	3.26 ± 0.20	94.16 ± 0.27
LTE4 low titer (mean ± SEM).	0.142 ± 0.004	2.79 ± 0.18 †	93.58 * ± 0.72
*P<0.05: Significant difference between patients and control group. †P<0.05: significant difference from the preceding value. RSV IgA : Respiratory Syncytial Virus Immunoglobuline A. LT-E4: Leukotriene E4. LOS: of hospital stay; S _p aO ₂ = blood oxygen saturation.			

Table (4) showed the effects of host factors on the length of hospital stay (LOS) and oxygen saturation (S_pO₂) in infants patients with acute viral bronchiolitis. As the table shown, only the host factors of family history of atopy and breast feeding of infants showed significant effects on duration of hospital stay and oxygen saturation of blood.

Concerning nasal swab from infants' patients with acute viral bronchiolitis before and after treatment with montelukast chewable 4 mg tablets once daily; according to Meltzer grading there was a significant

differences in the count of eosinophils –neutrophils before and after treatment with montelukst ; 1.6 ± 0.32 versus 0.33 ± 0.16 respectively. This could indicated eosinophil-recruiting chemokines were strongly produced and released from bronchial epithelial cells after in vivo stimulation with RSV.

IV. DISCUSSION

RSV is a highly infectious and prevalent virus. More than other respiratory viruses, **RSV** infection can occur very early in life despite maternal antibodies, and reinfection can readily occur throughout life without significant antigenic change. The relative contribution of viral versus various host factors to **RSV** pathogenesis remains controversial (6). The immune response to primary **RSV** infection is generally inefficient and consequently subsequent reinfections are common throughout life. In **RSV** infection, innate and adaptive immunity are out of balance (13).

Comparing the risk factors with **RSV** IgA values of infants' patients, only the age, history of atopy and passive tobacco smoking showed significant differences (14). In the age category older infants' patients (over 1 year) had significantly higher **RSV** IgA value compared to younger patients (below 1 year). Patients with negative family history of atopy had significantly higher **RSV** IgA value compared to patients with positive history of atopy. On the other hand patients with positive history of passive tobacco smoking had significantly higher **RSV** IgA value compared with those of negative history of passive tobacco smoking. This could indicate that, parental smoking did not inhibit the production of anti-microbial IgA, suggesting that other factors are responsible for the increased susceptibility to infection in these infants. Infants who lived in tobacco smoking environments had increased severity of disease, as results of Th2 predominance, with decreased expression of Th1 cytokines⁽¹⁵⁾, and IgA titer was less effective for protecting against **RSV** infection⁽²⁾. Lanari et al. (2002)⁽¹⁴⁾, demonstrated that exposure to cigarette smoke, in general, seems to worsen the severity of the viral bronchiolitis.

Comparing the risk factors with LTE4 values, only the gender and family history of tobacco smoke showed significant difference. Concerning the gender, the value in female babies was significantly higher than male babies. This could indicate that the females infants had more severe **RSV** infections compared to male infants; this has been attributed to the tendency of parents to bring sick male babies to the hospital earlier than female babies⁽³⁾. CysLT increased in infants who exposed to the tobacco smoke. This could indicate that, the exposure to the tobacco smoke increases the severity of **RSV** bronchiolitis, which was described here by the increased level of LTE4 in the infants who lived in tobacco smoking environments^(16,17,18).

Comparing the effects of host factors (age, sex, family history of asthma, atopy, tobacco smoking, kerosene heating, presence of pets at home, breast or bottle feeding and number of family members) on the length of hospital stay and oxygen saturation in infants with acute viral bronchiolitis; only the host factors of

family history of atopy and breast feeding of infants showed a significant effects on duration of hospital stay and oxygen saturation of blood⁽¹⁹⁾. Infants with a positive family of atopy showed a shorter duration of hospital stay and a higher value of blood oxygen saturation compared to infants with acute viral bronchiolitis and have no family history of atopy. Breast feeding of infants with acute viral bronchiolitis showed a significant effects on the blood oxygen saturation and length of hospital stay. Breast feeding is protective, through either transfer of maternal antibody or enhancement of virus-specific lymphocyte transformation activity. Infants with breast feeding have a shorter length of stay and higher value of blood oxygen saturation relative to infants without having breast feeding and have bottle fed. This finding is substantiated further by the fact that infants with a higher O₂ saturation spent less time in the hospital than infants with a lower O₂ saturation⁽¹⁴⁾.

Regarding to the effects of **RSV** IgA level on the length of hospital stay and patients oxygen saturation, there were a significant effects on both length of hospital stay and patient oxygen saturation. Infants with low titer of **RSV** IgA showed longer period of hospital stay & lower values of oxygen saturation compared to the patients with a high titer of **RSV** IgA, which could indicated effects of immune response of the patients on the resolution of symptoms and the time at which patients were fit to the discharge^(7,20). Regarding to the effects of inflammatory mediators cysteinyl leukotriene and its metabolite LTE4 on the period of hospital stay and oxygen saturation of infants patients with acute viral bronchiolitis, there were a significant effects. High titers of LTE4 associated with prolong hospital stay and lower value of blood oxygen saturation. Female, younger infants, negative family history of atopy, and absence of breast feeding, showed longer period of hospital admission & lower value of blood oxygen saturation.

According to Meltzer grading there were a significant differences in the counts of eosinophils – neutrophils before and after treatment with montelukast tablet for the infants patients with acute viral bronchiolitis. This could indicate that eosinophil-recruiting chemokines are strongly produced and released from bronchial epithelial cells after stimulation with **RSV**⁽¹²⁾; and montelukast treatment has been shown to reduce eosinophils in nasal mucosa of infants⁽²¹⁾.

V. CONCLUSION

The relationships between risk factors and **RSV** IgA titer in infants with viral bronchiolitis, only age, family history of atopy and tobacco smoking showed significant effects. Patients with low titer of **RSV** IgA showed longer period of hospital stay & lower values of oxygen saturation comparing to the patients with a high

titer of RSV IgA. Concerning the relationships between risk factors of infants with bronchitis and leukotriene E4 level, only the gender and family history of tobacco smoke showed significant difference. There were a significant effects of high level of LTE4 on the period of hospital stay compared to the low level of LTE4.

Host factors of family history of atopy and breast feeding of infants showed significant effects on duration of hospital stay and oxygen saturation of blood. Infants exposed to postnatal cigarette smoke from the mother had a lower O₂ saturation than those not exposed. Infants with a family history of atopy especially a maternal history of asthma had a higher O₂ saturation. Infants with highest blood oxygen saturation, have shorter length of hospital stay.

There were significant differences in the count of eosinophils –neutrophils before and after treatment with montelukast, which could indicate that, there was a correlation between nasal eosinophil and severity of viral bronchitis.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Patrick, B C. Systematic review of the biology and medical management of respiratory syncytial virus infection. *Respir Care* 2003; **48**(3):209–231.
2. Fisher R.G, Crowe J.E, Johnson T.R, Tang Y, Graham B.S. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. *The Journal of Infectious Diseases* 1999; **180**:1324–7.
3. Chakravarti A, Kashyap B. Respiratory syncytial virus in lower respiratory tract infections. *Iran J Ped* June 2007, vol **17** (No 2): p: 123-128.
4. Amirav I, Luder A S, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchitis. *Pediatrics* 2008; **122**:1249–1255.
5. Kott K.S, Salt B.H, McDonald R.J, Jhawar S, Bric J.M, Joad J.P. Effect of Secondhand Cigarette Smoke, RSV Bronchitis and Parental Asthma on Urinary Cysteinyl LTE4. *Pediatric Pulmonology* (2008); **43**:760–766
6. Collins, P.L; Graham, B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. *Journal of Virology* 2007:1-39.
7. Collins P.L, Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. *Journal of Virology*, Mar. 2008; Vol. **82**, No. 5: p. 2040–2055.
8. Gupta P, Aggarwal A, Gupta P & Sharma K.K. Oral salbutamol for symptomatic relief in mild bronchitis: A double blind randomized placebo controlled trial. *Indian Pediatrics* 2008 ; volume **45**:547-552.
9. Diagnostic Automation, INC 2009. Respiratory virus IgA Elisa. *DAI Code #* 8:1-7.
10. Catalog No. CSB-E05176h. Human leukotriene E4(LT-E4) ELISA Kit. *Cusabio Biotech Co., Ltd* 1-11.
11. Shinohara M, Wakiguchi H, Saito H, Matsumoto K. Presence of eosinophils in nasal secretion during acute respiratory tract infection in young children predicts subsequent wheezing within two months. *Allergology International*. 2008; **57**:359-365.
12. D'costa G.F, Candes A.F, Shedje R. Quantitative cytology of nasal secretion and scrapings in children with perennial allergic rhinitis, a comparison of non-infected and infected conditions. *Bombay Hospital Journal* 2009, Vol. **51**, No. 4:1-5.
13. Mejías.A, Chávez-Bueno .S, Ríos .A.M, Fonseca-Aten. M, Gómez .A.M, Jafri H.S, Ramilo .O. Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention. *An Pediatr (Barc)* 2004; **61**(3):E2.
14. Bradley J.P, Bacharier L.B, Bonfiglio J, Schechtman K.B, Strunk R, Storch G, Castro M. Severity of respiratory syncytial virus bronchitis is affected by cigarette smoke exposure and atopy. *Pediatrics* 2005; **115**:e7-e14.
15. Flores P, Guimarães J, Guimarães J.M.V. Th1 and Th2 cytokine expression in nasopharyngeal secretions during acute bronchitis in children younger than two years old. *Allergol Immunopathol (Madr)*. 2011; **39**(1):3–9
16. Der Vaart H, Postma D.S, Timens W, Ten Hacken N H T. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. *Thorax* 2004; **59**; 713-721.
17. Sritippayawan S, Prapphal N, Wong P, Tosukhowong P, Samransamruajkit R, Deerojanawong J. Environmental tobacco smoke exposure and respiratory syncytial virus infection in young children hospitalized with acute lower respiratory tract infection. *J Med Assoc Thai* 2006; **89** (12): 2097-103.
18. Mao J.T, Tashkin D.P, Tsu I-Hsien, et al. Differential modulation of leukotriene b4 synthesis and degradation in human bronchoalveolar lavage cells by lipopolysaccharide and tobacco smoke. *Cancer Prev Res* 2008; **1**:266-274.
19. Crowcroft, N.S; Cutts, F; Zambon, M.C. Respiratory syncytial virus: an underestimated cause of respiratory infection, with prospects for a vaccine. *Commun Dis Public Health* 1999; **2**: 234-41.
20. Singleton R, Etchart N, Hou S, Hyland L. Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. *Journal of Virology*, Nov. 2003; Vol. **77**, No. 21p. 11303–11311.
21. Golden M.P, Gleason M.M, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. *Clinical and Experimental Allergy* 2006; **36**: 689–703.